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Treatment of acute renal failure. Acute renal failure is a life
threatening illness whose mortality has remained high since the
introduction of hemodialysis 25 years ago, despite advances in
supportive care. Acute renal failure is an extremely morbid and
costly disorder with a significant proportion of patients progress-
ing to end-stage renal disease requiring dialysis. To the nephrol-
ogist, acute renal failure remains an extremely frustrating disease,
because the pathophysiology is not well understood and the
limited therapeutic options force the nephrologist to sit on the
sidelines and wait for renal function to return. For example,
dialysis remains the only FDA-approved treatment for acute renal
failure, but dialysis may also cause renal injury that prolongs renal
failure. The purpose of this perspective is to understand the
results of the recent, largely negative, clinical trials in view of
recent advances in the epidemiology of ARF. This review will also
discuss diagnostic tools, strategies for improved design of clinical
trials, and other therapeutic interventions that will be needed to
properly treat acute renal failure in the 21st century.
Acute renal failure is a life threatening illness whose
mortality has remained high since the introduction of
hemodialysis 25 years ago despite advances in supportive
care. Acute renal failure is an extremely morbid and costly
disorder with a significant proportion of patients progress-
ing to end-stage renal disease requiring dialysis. To the
nephrologist, acute renal failure remains an extremely
frustrating disease because the pathophysiology is not well
understood and the limited therapeutic options force the
nephrologist to sit on the sidelines and wait for renal
function to return. For example, dialysis remains the only
FDA-approved treatment for acute renal failure, but dial-
ysis may also cause renal injury that prolongs renal failure.
Aspects of acute renal failure have been the subject of
many recent excellent reviews [1–5] and an entire issue of
Kidney International [6]. The purpose of this perspective is
to understand the results of the recent, largely negative,
clinical trials in view of recent advances in the epidemiology
of ARF. This review will also discuss needed diagnostic
tools, strategies for improved design of clinical trials, and
other therapeutic interventions that will be needed to
properly treat acute renal failure in the 21st century.
DETECTION OF ACUTE RENAL FAILURE
Acute renal failure is typically diagnosed by observing
rises in BUN and plasma creatinine and decreases in urine
flow rates over several days. Unfortunately, creatinine is a
suboptimal indicator of renal function during acute renal
failure because plasma creatinine is influenced by many
non-renal events that regulate creatinine generation, vol-
ume of distribution, and creatinine excretion (Fig. 1). Each
of these can be dramatically altered in acute renal failure.
For example, patients with ARF are often edematous,
which dilutes creatinine and slows recognition of ARF.
Also, creatinine is excreted by glomerular filtration and
tubular secretion. As GFR decreases, the amount of tubu-
lar secretion becomes an increasingly important fraction of
creatinine excretion, such that creatinine clearance overes-
timates GFR by 50 to 100% once the true GFR is less than
15 ml/min [7]. The dynamic relationship between creatinine
and GFR (Fig. 2) further erodes our ability to both detect
and quantify renal dysfunction during ARF. Moran and
Myers noted that a sudden fall in GFR to a constant low
level causes a slow increase in plasma creatinine; the rate of
rise depends on the new GFR but also on the rate of
creatinine generation and the volume of distribution of
creatinine [8]. A new steady state is reached when the
creatinine generation equals creatinine excretion. During
recovery from ARF, the reverse occurs. This dynamic
relationship has several consequences. First, it is difficult to
estimate GFR from plasma creatinine during these non-
steady state conditions. The continued rise in plasma
creatinine does not indicate that renal function has wors-
ened; rather, it indicates that a steady state has not been
achieved. GFR is a complicated function of the rate of rise
of the plasma creatinine, the patient’s baseline GFR, and
the presence of edema and altered creatinine production.
Second, large changes in GFR are initially manifested as
small changes in creatinine in the first one to two days after
renal injury. Since these changes are near the detection
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limits of a clinical laboratory, the diagnosis of ARF may be
delayed, especially in the setting of malnutrition or edema.
Third, the degree of renal dysfunction cannot be deter-
mined accurately until the new steady state is reached
(creatinine is stabilized), which typically takes one week.
Thus, both plasma creatinine and creatinine clearance are
poor markers of renal function in the setting of acute renal
failure. The early diagnosis of ARF would be aided by
discovery of a serum marker akin to troponin for myocar-
dial infarction, or a method that measures renal function
more rapidly than a standard three-hour clearance study
(Glofil).
EPIDEMIOLOGY OF ACUTE RENAL FAILURE
Incidence
In the past five years there have been major advances in
understanding the epidemiology of ARF. This is no small
feat, since we still lack a centralized registry of patients with
ARF. The incidence of azotemia (including pre- and post-
renal ARF), ascertained from DRG coding of hospital
discharge summaries, is projected to be approximately
275,000 per year in 1997 and increasing at a rate of 16,000
patients per year according to the yearly National Hospital
Discharge Survey. The incidence of ARF is harder to
ascertain. Since ARF is present in about 42% of patients
with azotemia [9], the incidence of intrinsic acute renal
failure is about 115,000 cases/year. Thus, intrinsic acute
renal failure qualifies as an orphan drug indication, which
has important implications for future drug discovery.
Etiology
Acute renal failure is caused by ischemic (50%) or
nephrotoxic (35%) injury to the kidney. About 15% of
acute renal failure is caused by acute tubular interstitial
nephritis or acute glomerular nephritis [2]. However, 50%
of hospital acquired acute renal failure is frequently multi-
factorial, for example, sepsis treated with aminoglycosides,
radiocontrast in patients receiving angiotensin-converting
enzyme inhibitors, or congestive heart failure patients who
develop sepsis or are treated with non-steroidal anti-
inflammatory agents. Studies from the 1980s found that the
major risk factors for ARF are hypotension, congestive
heart failure, septic shock, volume depletion in diabetic
Fig. 1. Factors that influence steady state
creatinine and glomerular filtration rate (GFR)
in acute renal failure (ARF).
Fig. 2. Dynamic relationship between creatinine and GFR in ARF.
Modified from Moran and Myers [8].
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patients, aminoglycoside use, or radiocontrast procedures
[10, 11]. Acute renal failure also occurs in about 15 to 25%
of patients after renal transplantation despite careful at-
tempts to optimize fluid status and increase renal perfusion
[12, 13]. There is an increased risk of acute renal failure if
the transplanted kidney is obtained from a marginal donor
who is either hypotensive with a rising creatinine at the
time of transplantation or is greater than 60 years old.
Post-transplant acute renal failure has tremendous morbid-
ity, since it prolongs the initial hospitalization and increases
the risk of acute and subsequent chronic rejection [12]. If
this acute renal failure could be prevented, it would be
possible to transplant more kidneys from marginal donors
and thus double the size of the donor pool [14]. This would
dramatically decrease the waiting time for renal transplan-
tation, which currently averages about three years.
Mortality
Acute renal failure is a devastating illness that is associ-
ated with a high risk of mortality. The mortality rate of
ARF was 91% during World War II, 68% in Korea, and
67% in Vietnam. Most [15, 16] but not all [17] studies have
shown a modest improvement in the mortality of ARF over
the last 15 to 20 years; however, the rate is still unaccept-
ably high. The mortality rate depends on underlying comor-
bid illnesses and, hence, location in the hospital (Fig. 3).
For example, simple acute renal failure in the presence of
no other underlying illnesses has about a 7 to 23% mortal-
ity, whereas the mortality of acute renal failure in an ICU
setting is 50 to 80% [2, 18–21]. Lian˜o et al recently found
that the morbidity of intrinsic ARF was 37% outside the
ICU and 78% in an ICU setting [21]. Survival after acute
renal failure is dramatically influenced by the severity of the
underlying illnesses and number of failed organs. The
mortality of ARF in patients on a ventilator is about 80%,
and mortality dramatically increases with increasing num-
bers of failed non-respiratory organs [20]. The mortality of
patients with ARF increases with the number of failed
organ systems both in ICU and non-ICU settings [21]. In a
recent trial of atrial natriuretic peptide (ANP), the average
mortality was much lower at 26% [22]. The study excluded
patients with severe non-renal illness, since treatment of
the renal disease would not dramatically influence their
outcome; hence, the study population was biased towards a
less seriously ill population [23].
Independent risk of mortality
The studies cited above suggest that acute renal failure is
merely an unfortunate complication that is a proxy for the
severity of the other medical problems. However, a recent
study found that the development of even mild acute renal
failure itself increases morbidity (Fig. 4 [24]). Levy, Viscoli
and Horwitz performed a cohort analysis study of over
16,000 patients undergoing radiocontrast procedures. They
identified 183 patients who developed contrast nephropa-
thy (defined as an increase in serum creatinine of at least
25% to at least 2 mg/dl), and matched them to patients of
similar age and baseline serum creatinine who underwent
similar contrast procedures without developing acute renal
failure. This small 25% change in serum creatinine may
reflect as much as a 50% reduction in GFR. Only 12% of
the index patients needed dialysis. The mortality rate in
patients without renal failure was 7% compared to 34% in
the index patients. After adjusting for differences in comor-
bidity, renal failure was associated with an odds ratio of
dying of 5.5 [24]. The innovative feature of this study was to
perform the analysis in a relatively healthy population of
patients. Thus, the high mortality rate is not explained by
the underlying comorbid conditions alone. Acute renal
failure should not be regarded as a treatable complication
of a serious illness. Instead, changes in creatinine level,
however small, should be taken seriously and trigger sub-
sequent steps to determine the cause and specific treatment
of the renal failure [24, 25].
Morbidity of acute renal failure
How does acute renal failure result in excess morbidity
and mortality? A recent study of patients who died after
developing acute renal failure found that the patients had
complicated clinical courses characterized by sepsis, bleed-
ing, delirium, and respiratory failure [24]. Many of these
events occurred after the onset of ARF, implying that renal
dysfunction results in a generalized disturbance. All of
these events are well recognized complications of acute
Fig. 3. Mortality of ARF partly depends on
co-morbidity. Data taken from [2, 18–20, 22].
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renal failure that should in theory be well treated by
effective control of uremia with dialysis. This study suggests
that the recognition of patients at risk, prevention of acute
renal failure, and early treatment of acute renal failure will
be much more effective than treatment of established acute
renal failure.
Severity of illness
Before discussing the treatment of ARF, one must have
an index of the severity of renal and comorbid illnesses that
is accurate in patients with ARF. One of the notable
advances in the last five years has been the development of
indices that accurately predict the severity or mortality
associated with acute renal failure. These indices will
become extremely important in the future to detect chang-
ing trends in acute renal failure as well as in the design of
randomized clinical trials. APACHE II or III scores, which
measure the severity of physiological impairment in ICU
patients, underestimate the risk of mortality of patients
with acute renal failure (Fig. 5) [26, 27]. APACHE scores
do not work, perhaps because the proportion of the score
allocated to renal failure is only 4%, which de-emphasizes
the independent mortality risk of ARF [26]. Recently,
ARF-specific severity of index scores have been developed
for all patients with ARF [28, 29], and ICU patients with
acute renal failure [27, 30–32]. For example, Lian˜o et al in
Madrid have developed an accurate index that has been
validated retrospectively and prospectively in several dif-
ferent patient populations (Fig. 6) [26, 29, 33]. The index
accurately predicted overall mortality in ICU (actual
71.5%, predicted 65%) and non-ICU ARF (actual 31.5%,
predicted 32%) [21]. This index represents an important
advance, since previous indices worked quite well in the
hospital in which they were developed, but failed when
transported to other settings [27]. Renal dysfunction ac-
counts for 21% of the index, and comorbid illnesses
account for the remainder [26]. This index is quite inter-
esting because it indicates the individual contributions of
oliguria, hypotension, jaundice, coma, and assisted ventila-
tion. The largest contribution is assisted ventilation, which
agrees with previous studies that have indicated the 80%
mortality of those developing acute renal failure while on a
ventilator. Some of these indices may eventually be useful
in evaluating the futility of treatment in severely ill patients;
however, patients with a Madrid ARF Study Group severity
of illness score greater than 0.9 have survived [21].
As discussed above, the overall mortality rate of ARF has
only modestly improved over the last several decades,
despite the provision of better supportive care. Several
explanations for this lack of dramatic improvement have
been proposed: worsening comorbidity, dialysis-induced
Fig. 4. ARF is an independent risk factor for
death. Data taken from study of Levy et al [24].
Fig. 5. Traditional indices of ICU mortality (APACHE III) underesti-
mate the risk of death in patients with ARF, whereas the Lian˜o Severity
of Illness score is accurate. Symbols are: (l) observed; () Lian˜o; (f)
APACHE III). Data are taken from [26, 27].
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morbidity, more invasive surgery in sicker patients, and
older patients. Are these explanations correct? McCarthy
at Mayo Clinic found that overall hospital morbidity de-
creased from 68% to 48% during the years of 1977 to 1979
and 1991 to 1993, respectively [16]. While the mean
APACHE II score was similar in both study periods, the
more recent group was older and had more points for
chronic health problems. Stratification by APACHE II
scores showed a dramatic improvement in mortality in
patients with low (36% to 11%) or moderate (75% to 35%)
APACHE II scores, with little change at high APACHE II
scores (100% to 85%). Despite the shortcomings of the
APACHE II score in ARF, the data suggest that advances
in patient care have had an impact on the treatment of
patients with ARF, despite an older population who typi-
cally have more chronic health problems and more risk
factors for the development of ARF. It would be interesting
to see a similar analysis using a renal severity of illness
score.
Risk stratification
While the major risk factors for ARF are well known
(ischemia, nephrotoxins, sepsis, etc.), the risk in individual
patients is not well characterized. For example, after car-
diac surgery, ARF requiring dialysis develops in 1 to 5% of
patients and is strongly associated with peri-operative
mortality and morbidity. Can this event be predicted?
Chertow and colleagues recently collected prospective data
from 43,600 patients from 43 VA hospitals during the years
1987 to 1995 [18]. The overall risk of ARF requiring dialysis
was 1.1%. The development of ARF requiring hemodialy-
sis increased the 30 day mortality by 15-fold, from 4.3% to
63.7%. They used the elegant statistical technique of
recursive partitioning to allocate the patients into several
distinct risk groups (Fig. 7), which allows the patients to be
given more accurate prognostic information before surgery.
It is hoped that similar analyses will be carried out for other
procedures associated with a high risk of ARF.
Taken together, the recent advances in the epidemiology
of acute renal failure are beginning to permit an accurate
prediction of outcome based upon the nature and severity
of the renal insult, and the severity of the non-renal
illnesses. This tie between incident population and pre-
dicted outcome is key to the success of future clinical trials,
since who to treat may be as important as how to treat.
PATHOPHYSIOLOGY
The pathophysiology of acute renal failure is quite
complex and not well understood. The pathophysiology is
generally viewed from several different viewpoints, or
paradigms, which have been the subject of several recent
reviews [2, 34]. The paradigms are summarized here to
show how they have impacted on the choice of drugs that
have been tested in clinical trials.
Hemodynamic paradigm
The hemodynamic paradigm, developed in the 1960s and
1970s, views the nephron as a series of pipes: the blood
enters, is filtered, and then the glomerular filtrate is
processed by the nephron [35]. As such, acute renal failure,
that is, the failure to produce good urine, could be pro-
duced either by vasoconstriction of the supplying vascula-
ture, impairment of the filtration process, obstruction of
the tubules, or backleak of urine into the interstitium. This
paradigm led to the testing of vasodilators (ANP, dopa-
mine), diuretics (furosemide, mannitol), and anti-obstruc-
tive agents (integrins) to prevent acute renal failure [36–
38].
Cell fate paradigm
The cell fate paradigm, developed in the 1980s and early
1990s, focuses on the fate of an individual polarized tubular
cell after it is injured [34]. After injury the cell becomes
stunned and loses its polarity. This stunned cell can either
undergo necrosis or apoptosis, or the cell can initiate a
repair program that would return the cell to its normal
polarized state. This paradigm assumes that repair follows
developmental pathways. Hence, researchers have focused
on the use of growth and differentiation factors elaborated
by the developing nephron (that is, IGF-1, HGF, EGF) in
animal studies. IGF-1 has been tested in clinical trials.
Interactive cell biology paradigm
In the early 1990s, it became apparent that these para-
digms ignored the anatomical complexities of the kidney.
Tubule cells act as immune cells and actively participate in
Fig. 6. Components of Lian˜o ARF Severity of
Illness score [26, 29, 33].
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immune and inflammatory events surrounding them. Cells
interact with each other and release inflammatory media-
tors and cytotoxic substances into their local environment.
The ischemic kidney produces a variety of inflammatory
mediators, including tumor necrosis factor-a (TNFa), in-
terleukin (IL)-1, IL-8, and macrophage chemoattractant
protein-1 (MCP-1) [39]. The kidney also synthesizes cyto-
toxic agents that injure tubular cells, including superoxide
and, more recently discovered, nitric oxide [40–42]. There
is good evidence for inflammation in animal studies, al-
though the human data are less certain. The animal studies
quite convincingly show that neutrophil infiltration during
the recovery phase causes a no-reflow phenomenon. The
neutrophils plug the blood vessels, prevent red cells from
passing, and thus increase the amount of ischemic damage.
This paradigm is supported by the ability of anti-neutrophil
agents, such as neutrophil depletion and anti-ICAM-1
antibodies, to decrease injury following ischemia reperfu-
sion [39, 43, 44]. This paradigm is supported by human
data, which show that dialysis membranes that activate
neutrophils prolong the course of acute renal failure [45]
and accelerate the decline in residual renal function in
patients newly started on chronic hemodialysis [46]. Animal
studies have shown that activated neutrophils deposit in the
kidney, where they increase renal damage [47]. This para-
digm has led to the testing of anti-platelet agents, anti-
inflammatory agents (such as a-MSH [42, 48] or IL-10 [49])
and nitric oxide inhibitors in animal studies. For example,
we have shown that the anti-inflammatory cytokine a-
melanocyte-stimulating hormone (a-MSH) prevents renal
ischemic injury even when started six hours after ischemia,
and is effective even in the absence of neutrophils [42, 48].
While none of these agents have been tested in clinical trials,
these agents deserve further research.
Some of the therapeutic agents have multiple mecha-
nisms of action and thus may not fit cleanly within a single
paradigm. For example, IGF-1 also has important hemo-
dynamic effects that increase GFR independent of effects
Fig. 7. Risk of ARF requiring hemodialysis in patients after cardiac surgery. Ovals represent important patient characteristics selected by recursive
partitioning analysis. Abbreviations are: Creat Cl, creatinine clearance; CABG, coronary artery bypass grafting only (without valve replacement); IABP,
intra-aortic balloon pump; PVD, peripheral vascular disease. Mortality rates: low (0.4%); average (0.9 to 1.4%); moderate (2 to 2.8%); high (5 to 6.1%);
very high (9.5%). Modified from [18].
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on cellular growth and differentiation [50]. IGF-1 also
decreases the inflammatory response to renal injury [51].
RGD peptides also bind to the vasculature [52]. a-MSH
also increases blood pressure and cardiac output during
hemorrhagic and anoxic shock [53, 54].
Pathophysiology of human acute renal failure
Which of these paradigms describes human ARF? Hu-
man ARF is caused by heterogeneous factors (ischemia,
nephrotoxins, etc.), and it is likely that the underlying
pathophysiology differs in each case. However, human
ARF is generally multi-factorial, so all three paradigms
may be involved to some extent. A definitive answer may be
impossible because of the relative lack of human biopsies
early in ARF, and the near complete absence of the
required functional measurements. I propose that the
paradigms are best judged by their ability to lead to the
development of clinically effective drugs. Ultimately, this
issue will be answered by the results of clinical, not animal,
trials. That many agents have multiple mechanisms of
action may cloud the resolution of this issue; however, the
ability to work at multiple levels may be quite helpful for
successful treatment of human ARF.
NON-DIALYTIC TREATMENT OF ACUTE RENAL
FAILURE
Acute renal failure can be treated by inhibiting injury or
enhancing repair, or the injury process itself managed by
treating the metabolic consequences of acute renal failure
[reviewed in 2, 3, 55, 56]. These consequences include
volume overload, solute overload (hyperkalemia acidosis,
uremia, cytokines), endocrine deficiencies (erythropoietin),
and the non-renal complications, including sepsis, gastro-
intestinal (GI) bleeding, delirium, and respiratory failure.
The current treatment for ARF is empirical, that is, agents
are used indiscriminately without regard to underlying
etiology, with the hope that these agents will influence the
course of acute renal failure. At the present time, more
often than not this hope remains unfulfilled. Many agents
are effective in animal models; however, most of these
agents are effective only if started before injury. Since
clinicians are generally not present at the time of injury, it
is important that any pharmaceutical agents are effective
when started after the injury has occurred (Table 1; for
example, see [36, 37, 42, 57–59]).
Diuretics and mannitol (hemodynamic paradigm)
Furosemide is a loop diuretic and a vasodilator; it may
decrease the metabolic work of the thick ascending limb
and may flush obstructing casts from the nephron [60]. In
addition, furosemide may decrease the concentration of
toxins such as myoglobin or hemoglobin in the tubules.
Based on the hemodynamic paradigm, furosemide should
prevent ARF. In normal patients, furosemide does cause a
large diuresis. In some patients with ARF, furosemide may
convert oliguric ARF to non-oliguric ARF. However, there
is no solid evidence that furosemide alters the natural
history of human acute renal failure [56, 60–62]. The single
randomized controlled trial did not show any change in
azotemia or mortality [63]. Indeed, furosemide may worsen
radiocontrast-induced acute renal failure [64]. Conversion
of oliguric ARF to non-oliguric ARF simplifies the patient
management because the patient can receive a more liberal
fluid intake and it is easier to administer parenteral nutri-
tion. However, the conversion does not alter the natural
history of the disease, but instead supplies prognostic
information that the patient had less severe ARF. Large
doses of furosemide are ototoxic, and the large infusion
volume can cause pulmonary edema [65]. Thus, it is
reasonable to give a single trial of furosemide in escalating
doses. If the patient does not respond to furosemide, the
agent should not be readministered.
Mannitol is a diuretic that also may scavenge extracellu-
lar free hydroxyl radicals, although the importance of this
effect on ARF is unknown. Use of mannitol in ARF has
been comprehensively reviewed recently [66]. Mannitol is
beneficial when added to organ preservation solutions
during renal transplantation [67]. Mannitol may also pro-
tect against ARF caused by crush injury involving myoglo-
binuria, but only if given extremely early [66]. Other than
these limited uses, mannitol has not been shown to be
useful in prevention or treatment of ARF. In contrast,
mannitol aggravates radiocontrast induced ARF [64].
Renal low dose dopamine (hemodynamic paradigm)
Dopamine is a selective renal vasodilator that causes
profound natriuresis and increases urine output. It is widely
used despite little clinical data supporting its use. The renal
selective dose of dopamine is about 1 mg/kg/min and not 3
to 5 mg/kg/min as routinely used [68]. The use of dopamine
was examined in the placebo group of a recent randomized
control trial of atrial natriuretic peptide. Dopamine did not
improve survival or delay dialysis [69]. A recent review by
Denton, Chertow and Brady concludes that “the routine
Table 1. Interventions that prevent acute renal failure (ARF) in animal
studies
Paradigm Before injury After injury
Hemodynamic Diuretics ACE inhibitor (30 min)
Mannitol Phosphodiesterase inhibitor
(24 hrs)
Dopamine ANP (48 hrs)
Calcium channel blocker Endothelin antagonist
(48 hrs)
Endothelin antagonist
Cell fate IGF-1, EGF, HGF IGF-1 (24 hrs)
Interactive
cell biology
SOD-antagonist PAF antagonist (30 min)
anti-sense iNOS oligo ICAM-1 antibody (2 hrs)
P-selectin antagonist a-MSH (6 hrs)
CLTA-4lg
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use of dopamine should be discouraged until it is shown to
be effective” [68].
Atrial natriuretic peptide (hemodynamic paradigm)
Atrial natriuretic peptide (ANP) vasodilates the afferent
arteriole and constricts the efferent arteriole, resulting in
an increase in GFR. ANP also inhibits tubular sodium
absorption. The net effect is dramatic increase in urine
output. ANP is very effective in animal models even if first
started two days after the ischemic or nephrotoxic insult
[36, 37]. Because of these dramatic effects in animal
studies, an open label trial of ANP was performed at the
University of Colorado [70]. Fifty-three patients were se-
lected based on a rise in creatinine of 0.7 mg% per day for
three days. ANP had dramatic effects: it doubled the GFR
and reduced the need for dialysis by almost 50%. Based on
these positive results, a multicenter, randomized, double-
blind, placebo-controlled trial in 504 critically ill patients
with intrinsic acute renal failure was initiated [22]. Patients
were included if they had an increase of creatinine greater
than 1 mg over 48 hours. Many of the patients were
critically ill; 85% of the patients were in the ICU; 50% of
the patients were intubated. Patients were excluded if they
were hypotensive despite pressors. The trial had an excel-
lent balanced randomization, which was probably aided by
the large size of the trial. However, ANP had no effect on
21-day dialysis-free survival, mortality, or change in plasma
creatinine. A pre-specified subgroup analysis suggested
that ANP improved dialysis-free survival in oliguric pa-
tients (baseline creatinine clearance 4 ml/min), but not in
non-oliguric patients (baseline creatinine clearance 13 ml/
min). It was hypothesized that ANP was ineffective in
non-oliguric patients because the ANP induced hypoten-
sion and caused fresh ischemic injury. While the oliguric
group was also hypotensive, their kidneys were already
injured and evidently not subject to additional hypotensive
ischemic injury. Of note, if ANP converted oliguric acute
renal failure to non-oliguric acute renal failure, the out-
come was improved. A follow-up randomized controlled
clinical trial of ANP in oliguric patients with acute renal
failure was initiated, but halted after an interim analysis
showed that the trial was unlikely to find any therapeutic
benefit.
Insulin-like growth factor-1 (cell fate paradigm)
Insulin-like growth factor-1 (IGF-1) is made in high
concentrations by the developing kidney, where it induces
cell proliferation and differentiation. It was hypothesized
that IGF-1 might potentiate renal repair mechanisms after
renal injury, since the cell fate paradigm states that repair
recapitulates renal development [71]. In animal models of
renal injury, IGF-1 enhanced repair following renal isch-
emia even when started 24 hours after injury [59, 72], and
it may prevent renal injury following renal transplantation
in dogs [73]. IGF-1 also has direct hemodynamic effects
[50]. This agent was tested in two clinical trials. The first
trial, performed at Washington University in St. Louis, was
a randomized, double-blind, placebo-controlled trial of 58
patients undergoing vascular repair of the renal arteries or
aorta [74]. The surgeries are associated with a relatively
high rate of acute renal failure, often approaching 25%.
IGF-1 was started post-operatively just as the patient
entered the Intensive Care Unit. IGF-1 was well tolerated
with no notable side effects. IGF-1 produced a modest
(' 8 ml/min) increase in creatinine clearance, whereas the
placebo group had a slight fall in creatinine clearance.
Thus, IGF-1 prevented the decline of GFR. There was no
effect on morbidity, mortality, or length of stay. However,
no patient needed dialysis in either group. Evidently the
surgeons did not inflict very much renal injury during the
operation. IGF-1 was also tested in a multicenter, random-
ized, double-blind, placebo-controlled trial [75]. The study
enrolled 72 ICU patients with acute renal failure caused by
surgery, trauma, hypertension, sepsis, or drugs of less than
six days duration. Initial iothalamate GFR on randomiza-
tion was 6.4 ml/min in the IGF-1 group and 8.6 ml/min in
the placebo group. These patients had severe renal injury.
Unfortunately, there was no difference in post-treatment
GFR, need for dialysis, or morbidity. On the basis of this
trial, testing of IGF-1 to treat or prevent acute renal failure
was discontinued. IGF-1 is still being tested for use as an
adjunct to nutritional supplementation in a variety of
wasting disorders, including acute and chronic renal failure,
and is being tested in kidney transplantation.
Nutritional support
Nitrogen balance is extremely negative in patients with
ARF, and protein catabolic rate (PCR) is very high [re-
viewed in 76, 77]. Nutritional supplementation increases
azotemia, which increases the need for renal replacement
therapy, so that nutritional support is frequently delayed in
these patients to obviate the need for dialysis. Initial studies
showed the benefit of essential amino acid supplementa-
tion, but subsequent studies have been conflicting [re-
viewed in 55, 56, 76]. However, these studies were per-
formed before the recent advances in parenteral nutrition
and dialysis techniques [55, 56, 76]. Most nephrologists
recommend that nutritional supplementation should not be
withheld to minimize azotemia.
Nephrologic consultation
Only one non-dialytic intervention has been successful in
improving the morbidity and mortality of acute renal
failure. There is new evidence that early consultation with
a nephrologist improves the outcome of patients with ARF
[78]. Mehta et al showed that nephrologic consultation was
delayed in 28% of ICU patients with ARF in the ICU [78].
Delay in consultation was associated with higher mortality,
longer ICU length of stay, and increased number of organ
systems failing at the time of consultation [78]. Delay in
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nephrologic consultation was likely if the degree of ARF
was underestimated because of low creatinine (4.5 mg%) or
high urine output (400 ml/day). The lower creatinine was
often a consequence of volume overload that diluted the
plasma creatinine, or severe malnutrition that decreased
creatinine generation. While delay in consultation may
have occurred in sicker patients and thus may be a proxy for
severity of illness, this study demonstrates that interven-
tions early in the course of ARF may influence outcome.
DIALYSIS
The role of hemodialysis in ARF has been reviewed
recently [79]. Dialysis is required in about 85% of patients
with oliguric ARF, and 30% of patients with non-oliguric
ARF. Retrospective studies have shown that dialysis is
better than no dialysis [63, 80], but establishing a dose-
response relationship has been very difficult. Dialysis is a
risky procedure, with risks of bleeding and hemorrhage
from the site of vascular access. Hypotension and arrhyth-
mias are frequently produced as a consequence of rapid
changes in compartment volumes. Finally, recent studies
reviewed below have suggested that dialysis itself may delay
the recovery of renal function with ARF. This may be
caused by hypotension or activation of the inflammatory
cascades by the blood-dialyzer interface. Hypotension oc-
curs frequently during the dialysis of sick ARF patients and
can cause recurrent ischemic renal injury. Animal studies
have shown that kidneys with ARF have impaired renal
autoregulation, and frequently have increased vasoconstric-
tion because of injury to the vascular endothelium, that
results in increased sensitivity to vasoconstrictors and a
deceased release of vasodilators [81, 82]. Thus, hypotension
in the setting of ARF causes additional ischemic injury
because of impaired autoregulatory response to hypoten-
sion.
Hemodialysis with biocompatible membranes
Dialysis with a bio-incompatible membrane elicits an
inflammatory response consisting of complement activation
and subsequent neutrophil activation. The amount of the
response can be easily measured by a transient neutrope-
nia, as the activated neutrophils are removed from the
circulation by the lungs. Animal studies have shown that
activated neutrophils are also deposited in the kidneys,
where they either infiltrate into the organs or block small
blood vessels and cause renal injury [47]. Recent prospec-
tive randomized studies by Schiffl et al [83] and Hakim,
Wingard and Parker [45, 84] have shown that dialysis with
biocompatible membranes shortens the course of non-
oliguric ARF, reduces hospitalization, and increases sur-
vival. Dialysis with biocompatible membranes resulted in
less complement generation, better survival from sepsis,
and fewer dialysis sessions [83, 85]. The results in the
Hakim trials were more striking in the non-oliguric patients
than the oliguric patients. Non-oliguric patients have
higher renal blood flow and GFR [22], which may render
the kidney more susceptible to ischemic injury. A similar
selective deleterious effect of hypotension was also seen in
the ANP trial [22]. The biocompatible membrane trials
have been criticized because the criteria for dialysis was not
defined, and the decision was left to the discretion of the
nephrologist. However, subsequent analysis showed that
the two groups had similar blood chemistries at the time of
initiation and discontinuation of dialysis [84]. The hypoth-
esis is also supported by data showing that biocompatible
membranes preserve residual function in patients on
chronic hemodialysis [46], and that bioincompatible mem-
branes are associated with a higher rate of infections [86].
These positive results have not been reproduced in ARF
after renal transplantation [87] nor in several studies
published recently in abstract form [88–90]. A recent
abstract by Mehta et al of a non-randomized study showed
that the effect of dialyzer membrane on mortality and renal
recovery was not significant when patients were stratified
for APACHE III scores [91]; however, a more accurate
scale such as the Liano or Cleveland Clinical Severity of
Illness Score was not used. Finally, recent animal studies
did not find any differences between dialysis membranes
and recovery of renal function [92, 93]. Unlike the study by
Schulman et al [47], the rats received hemodialysis rather
than injection of complement activated plasma. On the
other hand, the exposure to dialysis membranes was short,
and only after the renal injury was established. Thus, the
issue remains very controversial. Nevertheless, the pub-
lished randomized trials do show impressive effects.
Does more dialysis enhance survival?
Retrospective trials have shown that dialysis used to keep
BUN below 150 mg% improves survival, when compared to
no dialysis [63, 80]. However, establishing whether more
dialysis is beneficial has been extremely difficult. Conger
performed a paired (not randomized) trial during the
Vietnam war, and found that sufficient dialysis to keep the
pre-dialysis BUN below 150 mg% caused an 80% mortality,
while more dialysis to keep the pre-dialysis BUN below 70
was associated with a 36% mortality [94]. Unfortunately,
because of the small size of the trial (8 to 10 patients per
group), the difference was not statistically significant. In a
prospective trial by Gillum et al that included a better
randomized design [95], the more intensive dialysis (de-
fined to keep BUN below 60 mg%) had less GI bleeding,
but the mortality in the intensive dialysis group was higher
(59%) than in the non-intensive group (47%) dialyzed to
keep the predialysis BUN below 100 mg%.
Paganini et al recently showed a link between dialysis
therapy and outcome in ICU patients with ARF; however,
this link was only present when the underlying comorbidity
was taken into account using the Cleveland Clinic Severity
of Illness Score [19]. This severity of illness score incorpo-
rates male gender, intubation/mechanical ventilation,
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platelet and leukocyte count, bilirubin level, number of
organ failures, change in BUN since admission, and serum
creatinine. This index shares some similar variables (intu-
bation, bilirubin) with the Liano index, although there are
differences of which the gender is most notable. Without
factoring for comorbidity, dialysis had no effect on survival.
When comorbidity was taken into account, dialysis had no
effect at the two ends of the spectrum: mortality of 0% in
patients with very low (,4) severity of illness scores and
nearly 100% at high (.15) scores (Fig. 8). However, the
dose of dialysis did affect outcome in patients with an
intermediate score. Higher delivery of dialysis (URR 58%,
Kt/V 1, TAC urea 45 mg%) was associated with significant
reduction in morbidity when compared to low dose delivery
in the same severity of illness quartile. Whereas the under-
lying patient morbidity has a significant effect on survival in
ARF, the dose of dialysis also plays a major role in patients
with intermediate severity of illness.
Schiffl et al have recently reported the preliminary
results of a trial in 72 critically ill patients with ARF who
were randomized to either daily or alternative day dialysis
using biocompatible high-flux dialyzers [96]. The two
groups were well matched in age, severity of ARF,
APACHE II scores, and prescribed dialysis techniques.
Overall mortality was significantly improved in the daily
dialysis group (21% vs. 47% for the alternative day group).
When analyzed in terms of delivered dialysis dose (Kt/V),
mortality was 16% in the group receiving a weekly Kt/V
greater than 6, which was significantly less than the 57%
mortality in patients receiving underdialysis (weekly
Kt/V , 3). This is the first study to show that the amount
of dialysis is an independent determinant of mortality in
critically ill patients with acute renal failure. Why did this
trial have a positive result that was not seen in previous
trials? Unlike previous dosing trials, this trial used biocom-
patible synthetic membranes, which may have allowed an
effect of dialysis dose to be seen for the reasons discussed
above. The study also suggests that the alternative day
dialysis typically prescribed for acute renal failure is ‘grossly
inadequate.’ More studies are needed to define how to
measure dialysis dose in patients with acute renal failure
[97]. Recent studies in chronic renal failure have found that
equilibrated or ‘double pool’ Kt/V is more accurate than
the traditional single pool Kt/V [98, 99]. Whether reliance
on equilibrated kinetics is also more accurate in acute renal
failure is unknown.
Mode of renal replacement therapy
In the past, intermittent hemodialysis (IHD) has been
the therapy of choice for ARF, since peritoneal dialysis
does not remove sufficient solute or volume. However,
IHD is associated with wide swings in body wt, blood
pressure, ventricular filling pressures, and solute concen-
trations (BUN, potassium, and bicarbonate). Because of
the concern that recurrent hypotension perpetuates renal
injury and lengthens recovery from ARF, newer modes of
dialysis therapy have been developed that minimize hypo-
tension. Continuous renal replacement therapy (CRRT)
removes fluid and solutes at a slow and controlled rate, thus
minimizing hypotension [reviewed in 91, 100–102]. Be-
cause it is more complicated to perform, CRRT is usually
reserved for hemodynamically unstable patients (including
those with sepsis, burns, and multiple organ dysfunction
syndrome) in the ICU who often cannot tolerate the
hemodynamic effects of intermittent hemodialysis. The
solute clearance of CRRT may be larger than IHD with
four treatments a week. The CRRT dialysis membrane has
large pores that may allow removal of inflammatory cyto-
kines. CRRT also allows for easier drug dosing. Because of
its theoretical advantages, it was hoped this would lead to
improved patients survival or recovery from renal failure.
IHD and CRRT have been compared in many non-
randomized or retrospective studies [reviewed in 55, 56,
102]. Prospective randomized trials are difficult to perform
because the hemodynamically unstable patients cannot
tolerate hemodialysis, while it may be ethically problematic
to confine a hemodynamically stable patient to bed while
receiving CRRT. A recent prospective trial from Barcelona
failed to find any difference in survival [103]. Mehta et al
recently completed a multi-center prospective randomized
trial of CRRT versus IHD in IHD patients with ARF [91].
One hundred and sixty-six patients were randomized to
receive either IHD or CRRT (which was performed as
CAVH or CAVHD). The total mortality was only 50%,
which was less than that expected from historical studies.
An intention to treat analysis found that the mortality was
Fig. 8. More dialysis enhances survival. Data from [19]. Symbols are (F)
more dialysis; (l) less dialysis.
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higher in the patients randomized to CRRT (65.5%) than
IHD (47.6%). Unfortunately, the randomization did not
balance the groups very well; for example, the APACHE
III scores were significantly different (85 for IHD vs. 102
for CRRT). Attempts to control for the unbalanced ran-
domization using the APACHE scores still led to the same
conclusion. Mehta et al have not reported their results
using either the Lian˜o or Paganini severity of illness scales,
which are more appropriate for renal patients. Subgroup
analyses suggest a beneficial effect of CRRT, since patients
who crossed over from IHD to CRRT had a higher
mortality than those who crossed over from CRRT to IHD.
Also, despite the higher mortality in the CRRT group,
patients initially treated with CRRT had higher rates of
recovery of renal function. At the present time, it appears
that intermittent hemodialysis and chronic renal replace-
ment therapy are roughly equivalent methods for treatment
of ARF.
PROBLEMS WITH CLINICAL TRIALS
Why did so many of the clinical trials fail? Did the
interventions lack efficacy, or were there problems in the
design of the clinical trails? If the former is true, then the
hemodynamic and cell fate paradigms may not be very
useful in guiding drug development. More research may be
needed to gain a better understanding of the underlying
pathophysiologic mechanisms responsible for human acute
renal failure. Perhaps we need better animal models that
more closely mimic human multi-factorial ARF. Since
human ARF is likely to have a diverse pathophysiological
basis, future trials may need to study the effects of several
agents at once or in a sequential order, as is used in cancer
chemotherapy. While these issues are difficult to resolve at
this time, I think that there is much to learn from the design
of the recent trials.
Delayed diagnosis and randomization
In all of the trials, ARF was diagnosed based upon
changes in plasma creatinine, which, as discussed above,
delays recognition of renal injury and does not allow
accurate assessment of the degree of renal damage. As a
result, the interventions may have been started too late to
be effective. For example, in the ANP trial the average
creatinine at the time of randomization was 4.5 mg%. If
creatinine rises at 1 to 2 mg%/day, this would indicate a
delay of two to four days from the time of injury. In the
IGF-1 trial, patients were enrolled within six days of injury.
The animal data suggests that the interventions must be
started early in the course of ARF (Table 1); effective
treatment of human ARF will likely also require prompt
treatment. We need a blood or urine test that measures
release of a renal-specific protein akin to cardiac tropopo-
nin used in the diagnosis of myocardial infarction. Alter-
natively, ARF could be diagnosed with a rapid functional
test that directly measures the extent of renal injury. For
example, GFR can be accurately measured by creatinine
clearance using a single dose of oral cimetidine to block
tubular secretion of creatinine [104]. We are evaluating a
new test that can measure GFR in 45 minutes. These tests
would allow rapid determination of renal dysfunction, and
therefore speed diagnosis and randomization, and perhaps
increase the efficacy of therapeutic drugs.
Wrong target population
Some of the trials enrolled patients who did not need
treatment or had severe renal injury that was unlikely to
respond to any interventions. For example, the IGF-1
prevention trial enrolled patients with a GFR 50% of
normal, and none of the patients needed dialysis [105].
These patients had very mild ARF, which would make it
difficult to detect a small protective effect of the interven-
tion. The unpublished ANP trial included patients with
severe oliguric ARF, which probably corresponds to a
creatinine clearance of 4 ml/min based upon the published
ARF study [22]. Since creatinine overestimates GFR by
about 25 to 50% in ARF, these patients had severe renal
injury.
Choosing the target population is of critical importance
to the design of a clinical trial [106]. A general rule is to
select patients who are most likely to benefit from the study
drug based upon the known mode of action of the drug and
the postulated effect size. The IGF-1 trials and Paganini’s
dialysis study suggest that treatment should be aimed at
patients with ‘moderate’ ARF (Fig. 9), either based upon
moderate renal injury or moderate predicted mortality.
Whereas the traditional daily creatinine cannot identify
patients with moderately severe renal dysfunction, these
patients may be identified by cimetidine-creatinine clear-
ance or other rapid GFR tests described above. A second
approach would be to enroll patients who are predicted to
have moderate mortality (perhaps 20 to 55%) at the time of
randomization. While general mortality estimates underes-
timate mortality in ARF (Fig. 5), the Liano and Cleveland
Clinic ARF Severity of Illness Scores are accurate in
hospitalized and ICU patients, respectively. Future ver-
sions of these scores are needed to predict the severity of
renal and non-renal diseases and the need for dialysis, and
to more accurately predict the mortality. Recent ANP and
IGF-1 trials had overall mortalities in this range [22, 75],
because they excluded patients with hypotension and se-
vere non-renal illnesses such that improvement in renal
function would not be expected to improve the clinical
outcome. However, the addition of more formal inclusion/
exclusion criteria may target the study to a more homoge-
nous patient population.
Studies aimed at preventing ARF must also consider the
incidence of ARF. Since ARF is rare in hospitalized
patients, the target population must be enriched in patients
who will develop ARF, to maintain a realistic study size.
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Unbalanced randomization
Human acute renal failure is a heterologous disease with
multiple etiologies, a wide range of severity, and a heter-
ogenous clinical outcome as discussed above. The heterog-
enous nature of ARF may promote unbalanced random-
ization, particularly in small trials. Whereas the placebo
and ANP groups were well matched in the large scale Phase
III trial of ANP involving 504 patients [22], there were
significant differences in gender, severity of illness
(APACHE II, APACHE III, and organ failure score), and
presence of liver disease between the two groups in Mehta’s
CVVH versus intermittent hemodialysis trial of 166 pa-
tients [107]. While trial results can be adjusted for these
factors using logistic regression, this post-hoc adjustment
makes the trial results harder to interpret. One potential
solution is to stratify patients before randomization using a
severity of illness score. This may ensure balanced random-
ization in a disease that is notorious for its heterogenous
clinical course.
Poorly defined endpoints
Dialysis was a so-called ‘hard’ endpoint in many of the
trials. However, the decision to dialyze, a key endpoint, is
usually left to the attending nephrologist. None of the trials
controlled for the application of dialysis by setting up
uniform criteria for initiating dialysis. Future trials using
dialysis as an endpoint should set uniform criteria for
starting and dosing dialysis treatments. This level of con-
formity may be difficult to achieve in a large multi-center
trial, or even in a single large group practice. However,
despite the lack of pre-specified criteria, a recent trial of
dialysis membranes in ARF did have similar blood chem-
istries in the two groups at the time of dialysis initiation and
at dialysis discontinuation [84].
Confounding effects
None of the trials controlled for the confounding effects
of non-study drugs, especially diuretics and dopamine.
These drugs do not benefit patients with ARF, and may do
considerable harm [64, 68]. Future trials of new agents
should exclude these drugs after randomization has oc-
curred.
REQUIREMENTS FOR EFFECTIVE TREATMENT OF
ACUTE RENAL FAILURE IN THE 21ST CENTURY
Management of acute renal failure is still a medical
challenge to clinicians, since the current treatment of ARF
is supportive. A more pro-active approach to acute renal
failure is outlined in Table 2. Use of this approach would
require the development of new tests to rapidly diagnose
and determine the severity of ARF, and new drugs to
prevent or treat ARF. Recent animal studies have identi-
fied new pharmaceutical agents that might lead to effective
drugs able to modify the course of ARF, most importantly
by primary prevention or, failing that, by treatment of
established ARF to lessen additional injury and promote
recovery [108]. Emerging therapies to watch include new
natriuretic peptides (urodilation [109]), anti-inflammatory
agents (a-MSH [42], anti-ICAM-1 antibodies [43, 44], and
p-selectin antagonists [110]), PAF antagonists [58], anti-T-
cell ligands (CTLA4-Ig [111]), and anti-integrin peptides to
prevent tubular cell obstruction [38]. Several of these
agents may need to be given simultaneously or sequentially,
similar to cancer chemotherapy. The recent negative clini-
cal trials have taught us the importance of early detection
of ARF, enrolling mid-range patients, and stratifying en-
rolled patients by severity of illness. A consensus statement
from a NIH-sponsored conference titled “Acute Renal
Failure in the 21st Century” in May 1996 has advocated the
development of a multicenter clinical trial network to
develop appropriate outcome measures and severity of
illness scores [3]. This group could also perform random-
ized trials to test the impact of hemodynamic monitoring,
new pharmacologic agents and nutritional therapy, and to
determine the optimal mode and amount of dialysis to
deliver. Since dialysis does not replace the reabsorptive,
homeostatic, metabolic, and endocrinologic functions of
the renal tubule, a bioartificial kidney that uses progenitor
Fig. 9. Who to enroll in clinical trials with acute renal failure.
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epithelial cells may also be helpful in specific situations
[112]. We wish to actively prevent or treat acute renal
failure. No more sitting on our hands.
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